18 related articles for article (PubMed ID: 9311620)
1. Pharmacokinetic and pharmacodynamic study of a new nonsteroidal 5 alpha-reductase inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-yl]-butyr ic acid, in rats.
Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
J Pharmacol Exp Ther; 1998 Mar; 284(3):914-20. PubMed ID: 9495849
[TBL] [Abstract][Full Text] [Related]
2. Novel steroid 5 alpha-reductase inhibitor FK143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes.
Kojo H; Nakayama O; Hirosumi J; Chida N; Notsu Y; Okuhara M
Mol Pharmacol; 1995 Sep; 48(3):401-6. PubMed ID: 7565619
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of FK143, a nonsteroidal inhibitor of steroid 5 alpha-reductase, in healthy volunteers.
Katashima M; Irino T; Shimojo F; Kawamura A; Kageyama H; Higashi N; Miyao Y; Tokuma Y; Hata T; Yamamoto K; Sawada Y; Iga T
Clin Pharmacol Ther; 1998 Mar; 63(3):354-66. PubMed ID: 9542479
[TBL] [Abstract][Full Text] [Related]
4. Preventive effect of FK143, a 5alpha-reductase inhibitor, on chemical hepatocarcinogenesis in rats.
Maruyama S; Nagasue N; Dhar DK; Yamanoi A; El-Assal ON; Satoh K; Okita K
Clin Cancer Res; 2001 Jul; 7(7):2096-104. PubMed ID: 11448929
[TBL] [Abstract][Full Text] [Related]
5. 4-(1-benzoylindol-3-yl)butyric acids and FK143: novel nonsteroidal inhibitors of steroid 5 alpha-reductase (II).
Sawada K; Okada S; Golden P; Kayakiri N; Sawada Y; Hashimoto M; Tanaka H
Chem Pharm Bull (Tokyo); 1999 Apr; 47(4):481-91. PubMed ID: 10319427
[TBL] [Abstract][Full Text] [Related]
6. Tissue distribution kinetics of a new nonsteroidal 5 alpha-reductase [correction of 5 A-reductase] inhibitor, 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-YL ]-butyric acid, in rats.
Katashima M; Yamamoto K; Haraguchi K; Tokuma Y; Hata T; Sawada Y; Iga T
Drug Metab Dispos; 1997 Sep; 25(9):1051-8. PubMed ID: 9311620
[TBL] [Abstract][Full Text] [Related]
7. Actions of 5alpha-reductase inhibitors on the epididymis.
Robaire B; Henderson NA
Mol Cell Endocrinol; 2006 May; 250(1-2):190-5. PubMed ID: 16476520
[TBL] [Abstract][Full Text] [Related]
8. Physiological pharmacokinetic modelling.
Balant LP; Gex-Fabry M
Xenobiotica; 1990 Nov; 20(11):1241-57. PubMed ID: 2275217
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
